|
|
Program Agenda
|
2009 Genitourinary Cancers Symposium Agenda
|
| |
|
2009 Genitourinary Cancers Symposium
A Multidisciplinary Approach
Program Agenda
Prostate Cancer - Thursday, February 26, 2009
Exhibit Hall Open
7:00 AM – 6:15 PM
Continental Breakfast Provided
7:00 AM – 8:00 AM
Welcome
8:00 AM – 8:15 AM
General Session I: Assessing Individual Prostate Cancer Risk
8:15 AM – 9:45 AM
Chair: Freddie Hamdy, MD, FRCSEd (Urol), FMedSci – University of Oxford
- Genetic Testing for Prostate Cancer: Clinical Hope?
Henrik Grönberg, MD, PhD – Karolinska Institutet, Sweden
“Should I Have a Prostate Biopsy, Doc?”
Robert Nam, MD, MSc, FRCSC – University of Toronto/Sunnybrook Health Sciences Centre
New Prognostic Markers: Pitfalls in the Pathway from Research to Clinical Practice
Andrew Vickers, PhD – Memorial Sloan-Kettering Cancer Center
Detection and Risk Stratification: Current State of the Art
Eric A. Klein, MD – Cleveland Clinic
Question and Answer Session
Break
9:45 AM – 10:15 AM
- General Session II: Treatment of Localized Prostate Cancer
10:15 AM – 12:00 PM
Chair: Deborah Kuban, MD – M. D. Anderson Cancer Center
- Postoperative Radiotherapy: Data from Clinical Trials
Alan Pollack, MD, PhD – University of Miami – Miller School of Medicine
Panel: Postoperative Radiotherapy: Discussion of Clinical Practice
Moderator: Adam Stuart Kibel, MD – Washington University School of Medicine
Panelists: Ian M. Thompson, MD – University of Texas Health Sciences Center
James E. Montie, MD – University of Michigan
Chris Parker, MD, MRCP, FRCR – Royal Marsden NHS Trust/Institute of Cancer Research
Howard Sandler, MD – Cedars-Sinai Medical Center
Question and Answer Session
A Randomized Trial of Cryotherapy versus External Beam Radiotherapy
Bryan J. Donnelly, MD – University of Calgary
Discussant: W. Robert Lee, MD – Duke University Medical Center
Is Focal Therapy Sham Therapy?
It is Sham Therapy: Michael Koch, MD – Indiana University
It is Not Sham Therapy: Mark Emberton, MD – University College London Hospital
Question and Answer Session
General Poster Session A & Fellows Poster Walk: Prostate Cancer (Box Lunch Provided)
12:00 PM – 1:15 PM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Oral Abstract Presentation Session A: Prostate Cancer
1:15 PM – 2:45 PM
Co-Chairs: Robert S. DiPaola, MD – The Cancer Institute of New Jersey
W. Robert Lee, MD – Duke University Medical Center
- Abstract (#1): The Selenium and Vitamin E Cancer Prevention Trial (SELECT): Southwest Oncology Group Study S0000
Eric A. Klein, MD – Cleveland Clinic
Abstract (#2): The PSA threshold for a prostate biopsy: Should it be lowered from 3.0 ng/ml to 2.0 ng/ml in a screening setting? (ERSPC Rotterdam)
Monique J. Roobol, PhD – Erasmus Medical Centre
Abstract (#3): Feasibility and clinical utility of a TMPRSS2:ERG gene fusion urine test
Jack Groskopf, PhD – Gen-Probe Incorporated
Discussant: Freddie Hamdy, MD, FRCSEd (Urol), FMedSci – University of Oxford
Abstract (#4): Defining the a/ß ratio for prostate cancer: results of a randomized radiotherapy hypofractionation trial
Alan Pollack, MD, PhD – University of Miami – Miller School of Medicine
Abstract (#5): The natural history of metastatic progression in men with PSA-recurrent prostate cancer (PCa) after radical prostatectomy: 25-year follow-up.
Emmanuel S. Antonarakis, MD – Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Abstract (#6): Survival benefit with oral sodium clodronate in metastatic but not localised prostate cancer: Long-term results of MRC PR04 & PR05
David P. Dearnaley, MD – The Institute of Cancer Research
Abstract (#7): A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC)
Eric J. Small, MD – University of California San Francisco
Discussant: Robert S. DiPaola, MD – The Cancer Institute of New Jersey
Break
2:45 PM – 3:15 PM
- General Session III: Treatment of Advanced Prostate Cancer
3:15 PM – 5:00 PM
Chair: Eric J. Small, MD – University of California San Francisco
- Using Circulating Tumor Cells to Guide Individual Patient Management
Howard I. Scher, MD – Memorial Sloan-Kettering Cancer Center
Clinical Drug Development in Castration-resistant Prostate Cancer: As Easy as (phase) I, II, III?
Johann de Bono, MD, FRCP, PhD, MSc – Royal Marsden NHS Trust/Institute of Cancer Research
Bone-targeted Treatment for Advanced Prostate Cancer
Oliver Sartor, MD – Tulane University School of Medicine
Question and Answer Session
Case Discussion of Complex Patients
Moderator: Eric J. Small, MD – University of California San Francisco
Panelists: Fred Saad, MD, FRCS, University of Montreal Hospital Centre
Cora Sternberg, MD, FACP – San Camillo Forlanini Hospital
Stephen Harland, MD, FRCP – University College London Hospital
Michael Morris, MD – Memorial Sloan-Kettering Cancer Center
General Poster Session B and Reception: Prostate Cancer (Wine and Cheese Provided)
5:00 PM – 6:15 PM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Penile, Testis, and Bladder Cancers - Friday, February 27, 2009
Best of Journals Session: Prostate Cancer
7:00 AM – 8:00 AM
Participants: Adam Stuart Kibel, MD – Washington University School of Medicine
Eric J. Small, MD – University of California San Francisco
Ian M. Thompson, MD – University of Texas Health Sciences Center
These are limited-attendance, ticketed sessions.
Exhibit Hall Open
7:00 AM – 6:00 PM
Continental Breakfast Provided
7:00 AM – 8:00 AM
Welcome
8:00 AM – 8:15 AM
- General Session IV: Penile Cancer: Current Concepts and Controversies
8:15 AM – 9:45 AM
Co-Chairs: Dean Bajorin, MD – Memorial Sloan-Kettering Cancer Center
Christine Haie-Meder, MD – Institute Gustave-Roussy
- Role for Penile Conservation
Curtis Pettaway, MD – M. D. Anderson Cancer Center
Juanita Crook, FRCPC, MD – Princess Margaret Hospital
Management of Inguinal Nodes: Prophylactic versus Therapeutic Node Dissection
W. Scott McDougal, MD – Massachusetts General Hospital
Advanced Primary and Concurrent Bulky Nodes, which May or May Not Be Resectable
Lance Pagliaro, MD – M. D. Anderson Cancer Center
Panel Discussion and Audience Q & A
Break
9:45 AM – 10:15 AM
- General Session V: Challenges in Advanced Testicular Cancer
10:15 AM – 11:45 AM
Co-Chairs: Michael Jewett, MD, FRCSC, FACS – Princess Margaret Hospital
Robert J. Motzer, MD – Memorial Sloan-Kettering Cancer Center
- Challenges and Initial Management of Disseminated Germ Cell Tumor
Craig Nichols, MD – Earle A. Chiles Research Institute
Relapsing Disease: Second-line Therapy and Beyond
Christian Kollmannsberger, MD, FRCPC – BCCA – Vancouver Cancer Centre
Management of Postchemotherapy Residual Masses
Joel Sheinfeld, MD – Memorial Sloan-Kettering Cancer Center
Abstract (#230): Complications of postchemotherapy retroperitoneal lymph node dissection for advanced testis cancer
Axel Heidenreich, MD – University of Cologne
Abstract (#231): Risk factors for thromboembolic events (TTEs) in testicular cancer patients receiving chemotherapy.
Katharine Shim, MD, FRCPC – London Regional Cancer Program
Question and Answer Session
General Poster Session C: Prostate Cancer (Box Lunch Provided)
11:45 AM – 1:15 PM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Fellows, Residents, and Junior Faculty Luncheon
11:45 AM – 12:45 PM
Co-Chairs: Dean Bajorin, MD – Memorial Sloan-Kettering Cancer Center
Eric A. Klein, MD – Cleveland Clinic
This is a limited-attendance, ticketed session.
Oral Abstract Presentation Session B: Penile, Testis, and Bladder Cancers
1:15 PM - 2:15 PM
Co-Chairs: Juanita Crook, FRCPC, MD – Princess Margaret Hospital
Cora Sternberg, MD, FACP – San Camillo Forlanini Hospital
Abstract (#227): Squamous cell carcinoma of the penis: Results of brachytherapy as primary management for 74 patients over an 18-year period
Juanita Crook, FRCPC, MD, Princess Margaret Hospital
Abstract (#228): Brachytherapy results in patients with penile glans squamous cell carcinoma
Christine Haie-Meder, MD – Institut Gustav-Roussy
Abstract (#232): Incidence of testicular cancer in the United States, 1999 - 2004
Julie Townsend, MS – Centers for Disease Control and Prevention
Abstract (#238): A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center
Arlene O. Siefker-Radtke, MD – M. D. Anderson Cancer Center
Abstract (#239): Clinical value of 18F-2-deoxyglucose positron emission tomography (FDG PET) in bladder cancer
Andrea B. Apolo, MD – Memorial Sloan-Kettering Cancer Center
Break
2:00 PM – 2:30 PM
- General Session VI: New Drugs and Treatment Strategies in Bladder Cancer
2:30 PM – 5:00 PM
Co-Chairs: Richard J. Cote, MD – USC/Norris Comprehensive Cancer Center
Robert Dreicer, MD – Cleveland Clinic
- Pathology and Molecular Biology of Bladder Cancer
Richard J. Cote, MD – USC/Norris Comprehensive Cancer Center
Biomarkers for Early Detection
Badrinath Konety, MD, MBA – University of California San Francisco
How to Manage Patients Who Fail Bacille Calmette-Guerin Therapy
Harry Herr, FACS – Memorial Sloan-Kettering Cancer Center
Novel Trial Designs in Bladder Cancer
Dean Bajorin, MD – Memorial Sloan-Kettering Cancer Center
Targeted Therapeutics in Urothelial Cancer: Early Results
Robert Dreicer, MD – Cleveland Clinic
Question and Answer Session
Case Discussion
Moderator: Seth P. Lerner, MD – Baylor College of Medicine
Panelists: Robert Dreicer, MD – Cleveland Clinic
Dean Bajorin, MD – Memorial Sloan-Kettering Cancer Center
Howard Sandler, MD – Cedars-Sinai Medical Center
Harry Herr, FACS – Memorial Sloan-Kettering Cancer Center
Richard J. Cote, MD – USC/Norris Comprehensive Cancer Center
General Poster Session D and Reception: Penile, Testis, and Bladder Cancer (Wine and Cheese Provided)
5:00 PM – 6:00 PM
Renal Cell Cancer - Saturday, February 28, 2009
No Exhibits
Best of Journals Session: Renal Cell Cancer
7:00 AM – 8:00 AM
Participants: Brian Rini, MD – Cleveland Clinic
Christopher G. Wood, MD, FACS – M. D. Anderson Cancer Center
Robert S. DiPaola, MD – The Cancer Institute of New Jersey
These are limited-attendance, ticketed sessions.
Continental Breakfast Provided
7:00 AM – 8:15 AM
Keynote Lecture and Welcome
Microfluidic Isolation and Molecular Analysis of Circulating Tumor Cells
Daniel Arie Haber, MD, PhD – Massachusetts General Hospital
8:15 AM – 9:00 AM
- General Session VII: Management of Multifocal Bilateral Renal Cell Carcinoma
9:00 AM – 10:30 AM
Chair: Allan J. Pantuck, MD, MS, FACS – UCLA School of Medicine
- Case Presentation
Role of Minimally-invasive Surgery with Robotics
Raju Thomas, MD, FACS, MHA – Tulane University School of Medicine
Case Update
Management of Recurrent Disease after Surgical Therapy
Gennady Bratslavsky, MD – National Cancer Institute
Case Update
When Should Genetic Syndromes be Considered?
Laura S. Schmidt, PhD – National Cancer Institute
Panel Discussion, Audience-Response System, and Question and Answer Session
- Chair: Allan J. Pantuck, MD, MS, FACS – UCLA School of Medicine
Raju Thomas, MD, FACS, MHA – Tulane University School of Medicine
Gennady Bratslavsky, MD – National Cancer Institute
Laura S. Schmidt, PhD – National Cancer Institute
Eric Jonasch, MD – M. D. Anderson Cancer Center
Break
10:30 AM – 11:00 AM
- General Session VIII: Targeted Therapy for Metastatic Disease
11:00 AM – 12:30 PM
Chair: Bernard Escudier, MD – Institut Gustave-Roussy
- Case Presentation
Bernard Escudier, MD – Institut Gustave-Roussy
Molecular Basis of Targeted Therapy Resistance
James W. Mier, MD – Beth Israel Deaconess Medical Center
Pharmacogenetics/Polymorphism: Side Effects and Comorbidity – Predisposition to Toxicity
Ram Ganapathi, PhD – Cleveland Clinic
mTOR Pathway: Biologic Rationale for Targeting in Renal Cell Cancer
George Thomas, MD – Institute of Cancer Research/Royal Marsden NHS Trust
Abstract (#278): Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC)
Robert Motzer, MD – Memorial Sloan-Kettering Cancer Center
Targeting the C-Met Pathway in Renal Cell Carcinoma
Patricia M. LoRusso, DO – Barbara Ann Karmanos Cancer Institute
Question and Answer Session
Abstract Presentation
General Poster Session E & Poster Walk: Renal Cell Cancer (Box Lunch Provided)
12:30 PM – 1:30 PM
Oral Abstract Presentation Session C: Renal Cell Cancer
1:30 PM – 3:00 PM
Co-Chairs: Bernard Escudier, MD – Institut Gustave-Roussy
Allan J. Pantuck, MD, MS, FACS – UCLA School of Medicine
Abstract (#280): Association of percentage of tumor burden removed with debulking nephrectomy and progression free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy
Juan Barbastefano, MD – Cleveland Clinic
Abstract (#281): Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features
Theodore Logan, MD – Indiana University Cancer Center
Abstract (#282): Cytoreductive nephrectomy for patients with advanced kidney cancer and sarcomatoid histology: Is up-front resection indicated, avoidable, and is there an alternative?
Brian Schuch, MD – University of California, Los Angeles
Discussant: Allan J. Pantuck, MD – UCLA School of Medicine
Abstract (#283): Activity and safety of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial
Pankaj Bhargava, MD – Aveo Pharmaceuticals, Inc.
Abstract (#284): Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study
Daniel Y. Heng, MD – Tom Baker Cancer Center
Abstract (#285): ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features
Naomi B. Haas, MD – University of Pennsylvania Abramson Cancer Center
Discussant: Bernard Escudier, MD – Institut Gustave-Roussy
Question and Answer Session
Break
3:00 PM – 3:30 PM
- General Session IX: Management of Locally-advanced/Regionally-metastatic Renal Cell Carcinoma
3:30 PM – 5:00 PM
Co-Chairs: Christopher G. Wood, MD, FACS – M. D. Anderson Cancer Center
Eric Jonasch, MD – M. D. Anderson Cancer Center
- Case Presentation
Outcomes with Locally-advanced Disease
Arie Belldegrun, MD – UCLA School of Medicine
Update on Adjuvant Therapy and Toxicity: Cardiac Toxicity
Naomi B. Haas, MD – University of Pennsylvania Abramson Cancer Center
Tyrosine-Kinase Inhibitors in a Presurgical Setting
Brian Rini, MD – Cleveland Clinic
Molecular Basis for Predicting Response to Targeted Therapy
M. Celeste Simon, PhD – University of Pennsylvania Abramson Cancer Center
Abstract (#279): Management of the adrenal gland during partial nephrectomy
Brian R. Lane, MD, PhD – Cleveland Clinic
Question and Answer Session
Adjourn
5:00 PM
|
|
|
